These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 10372695)

  • 1. Effect of testosterone treatment on bone mineral density in men over 65 years of age.
    Snyder PJ; Peachey H; Hannoush P; Berlin JA; Loh L; Holmes JH; Dlewati A; Staley J; Santanna J; Kapoor SC; Attie MF; Haddad JG; Strom BL
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1966-72. PubMed ID: 10372695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of testosterone replacement in hypogonadal men.
    Snyder PJ; Peachey H; Berlin JA; Hannoush P; Haddad G; Dlewati A; Santanna J; Loh L; Lenrow DA; Holmes JH; Kapoor SC; Atkinson LE; Strom BL
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2670-7. PubMed ID: 10946864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone.
    Amory JK; Watts NB; Easley KA; Sutton PR; Anawalt BD; Matsumoto AM; Bremner WJ; Tenover JL
    J Clin Endocrinol Metab; 2004 Feb; 89(2):503-10. PubMed ID: 14764753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone mineral density and response to treatment in men younger than 50 years with testosterone deficiency and sexual dysfunction or infertility.
    Kacker R; Conners W; Zade J; Morgentaler A
    J Urol; 2014 Apr; 191(4):1072-6. PubMed ID: 24161998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age.
    Snyder PJ; Peachey H; Hannoush P; Berlin JA; Loh L; Lenrow DA; Holmes JH; Dlewati A; Santanna J; Rosen CJ; Strom BL
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2647-53. PubMed ID: 10443654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis.
    Diamond T; Stiel D; Posen S
    J Bone Miner Res; 1991 Jan; 6(1):39-43. PubMed ID: 2048430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men.
    Basurto L; Zarate A; Gomez R; Vargas C; Saucedo R; Galván R
    Aging Male; 2008 Sep; 11(3):140-5. PubMed ID: 18821290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of hypogonadism and testosterone-enhancing therapy on alkaline phosphatase and bone mineral density.
    Dabaja AA; Bryson CF; Schlegel PN; Paduch DA
    BJU Int; 2015 Mar; 115(3):480-5. PubMed ID: 25046796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal testosterone therapy in the treatment of male hypogonadism.
    Ahmed SR; Boucher AE; Manni A; Santen RJ; Bartholomew M; Demers LM
    J Clin Endocrinol Metab; 1988 Mar; 66(3):546-51. PubMed ID: 3350906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome.
    Fairfield WP; Finkelstein JS; Klibanski A; Grinspoon SK
    J Clin Endocrinol Metab; 2001 May; 86(5):2020-6. PubMed ID: 11344201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys.
    Wickman S; Kajantie E; Dunkel L
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3785-93. PubMed ID: 12915670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of testosterone supplementation in the aging male.
    Tenover JS
    J Clin Endocrinol Metab; 1992 Oct; 75(4):1092-8. PubMed ID: 1400877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.
    Katznelson L; Finkelstein JS; Schoenfeld DA; Rosenthal DI; Anderson EJ; Klibanski A
    J Clin Endocrinol Metab; 1996 Dec; 81(12):4358-65. PubMed ID: 8954042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism.
    Merza Z; Blumsohn A; Mah PM; Meads DM; McKenna SP; Wylie K; Eastell R; Wu F; Ross RJ
    Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism.
    Zacharin MR; Pua J; Kanumakala S
    Clin Endocrinol (Oxf); 2003 Jun; 58(6):691-5. PubMed ID: 12780744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men.
    Behre HM; Kliesch S; Leifke E; Link TM; Nieschlag E
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2386-90. PubMed ID: 9253305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study.
    Bouloux PM; Legros JJ; Elbers JM; Geurts TB; Kaspers MJ; Meehan AG; Meuleman EJ;
    Aging Male; 2013 Jun; 16(2):38-47. PubMed ID: 23581697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate for the treatment of osteoporosis in men.
    Orwoll E; Ettinger M; Weiss S; Miller P; Kendler D; Graham J; Adami S; Weber K; Lorenc R; Pietschmann P; Vandormael K; Lombardi A
    N Engl J Med; 2000 Aug; 343(9):604-10. PubMed ID: 10979796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study.
    Aversa A; Bruzziches R; Francomano D; Greco EA; Fornari R; Di Luigi L; Lenzi A; Migliaccio S
    Aging Male; 2012 Jun; 15(2):96-102. PubMed ID: 22439807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.
    Orwoll E; Teglbjærg CS; Langdahl BL; Chapurlat R; Czerwinski E; Kendler DL; Reginster JY; Kivitz A; Lewiecki EM; Miller PD; Bolognese MA; McClung MR; Bone HG; Ljunggren Ö; Abrahamsen B; Gruntmanis U; Yang YC; Wagman RB; Siddhanti S; Grauer A; Hall JW; Boonen S
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3161-9. PubMed ID: 22723310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.